Corient Private Wealth LP Takes Position in Phreesia, Inc. $PHR

Key Points

• Corient Private Wealth LP acquired 120,380 Phreesia shares worth approximately $1.24 million, giving it a 0.19% stake. Institutional investors collectively own 92.1% of the company.
• Analyst sentiment is mixed: RBC and Canaccord maintained bullish ratings with price targets of $19 and $16, respectively, while the consensus rating remains Hold with an average target of $15.25.
• Phreesia’s latest quarter showed revenue growth of 10.4% year over year to $129.46 million, slightly beating estimates, but EPS of $0.03 missed consensus by $0.06. Shares recently traded near $10.97.

Corient Private Wealth LP purchased a new stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 120,380 shares of the company's stock, valued at approximately $1,239,000. Corient Private Wealth LP owned about 0.19% of Phreesia at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pale Fire Capital SE purchased a new position in Phreesia in the first quarter valued at approximately $72,481,000. BlackRock Inc. bought a new stake in shares of Phreesia in the second quarter valued at $72,234,000. Granahan Investment Management LLC lifted its position in shares of Phreesia by 73.8% during the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company's stock valued at $40,601,000 after buying an additional 1,018,987 shares during the last quarter. Prosight Management LP bought a new position in shares of Phreesia during the 4th quarter worth $16,533,000. Finally, Millennium Management LLC grew its stake in shares of Phreesia by 730.7% during the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company's stock worth $25,028,000 after acquiring an additional 936,033 shares during the period. Hedge funds and other institutional investors own 92.10% of the company's stock.

Analyst Upgrades and Downgrades

PHR has been the topic of several recent research reports. Citigroup reaffirmed a "market perform" rating on shares of Phreesia in a report on Friday. Truist Financial upped their target price on shares of Phreesia from $11.00 to $12.00 and gave the stock a "hold" rating in a report on Thursday, May 28th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $16.00 price target on shares of Phreesia in a report on Thursday. Wall Street Zen downgraded Phreesia from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $19.00 price objective on shares of Phreesia in a research note on Thursday. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $15.25.

Phreesia Stock Performance

Shares of PHR stock opened at $10.97 on Friday. The company has a market capitalization of $678.08 million, a P/E ratio of 64.53 and a beta of 0.86. Phreesia, Inc. has a fifty-two week low of $7.77 and a fifty-two week high of $30.43. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a 50 day moving average price of $11.25 and a two-hundred day moving average price of $10.47.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, September 2nd. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.06). The firm had revenue of $129.46 million during the quarter, compared to analysts' expectations of $129.06 million. Phreesia had a return on equity of 5.35% and a net margin of 2.06%.The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.01 earnings per share. Analysts expect that Phreesia, Inc. will post 0.39 earnings per share for the current year.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: RBC Capital reiterated a Buy rating on Phreesia, supporting the investment case despite recent earnings pressure. Phreesia Receives a Buy from RBC Capital
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $19 price target, while Canaccord Genuity reaffirmed its Buy rating with a $16 target. The targets imply substantial upside from the recent trading level and indicate analysts remain confident in Phreesia’s longer-term prospects.
• Positive Sentiment: Second-quarter fiscal 2027 revenue increased approximately 10% year over year to $129.5 million, slightly exceeding consensus expectations. Adjusted EBITDA reached $32.9 million, highlighting continued operating profitability and scale. Phreesia Q2 Fiscal 2027 Revenue Rises 10 Percent
• Neutral Sentiment: Analyst commentary remains constructive, but the wide gap between current trading levels and price targets suggests the market is waiting for clearer evidence that Phreesia can accelerate earnings growth.
• Negative Sentiment: Phreesia reported quarterly EPS of $0.03, below the consensus estimate of $0.09. The earnings shortfall overshadowed the revenue beat and likely drove the negative investor reaction. Phreesia Shares Sink After 2Q Earnings Underwhelm

About Phreesia

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source